Cortical lesions (CLs) are an important component of multiple sclerosis (MS) pathology; they correlate better with physical disability and cognitive impairment than white matter lesions (WMLs). Because remyelination can be extensive in CLs, we quantified remyelination in gray matter (GM) and white matter (WM), addressing oligodendrocyte (OGD) maturation state and clinical relevance of remyelination. Brain tissue samples from 21 chronic MS patients were immunohistochemically stained for myelin proteolipid protein, Olig2, which is strongly expressed in OGD precursor cells (OPCs), but weakly expressed in mature OGDs and other OGD markers. Sections were scored for the presence of normal-appearing WM and GM, de-and remyelination, and OPC and OGD cell counts. Remyelination was significantly more extensive in CLs than in WMLs with a trend toward more GM remyelination in primary progressive MS (PPMS) vs relapse-onset MS patients. More OPCs were found in remyelinated and nonremyelinated CLs vs remyelinated WMLs and nonremyelinated WMLs. Thus, there is more remyelination in the GM than in the WM in MS patient brains, with a trend toward more remyelination in those with PPMS. There does not seem to be a significant OPC recruitment failure in the GM, which casts new light on the process of remyelination failure.
INTRODUCTION
Multiple sclerosis (MS) has traditionally been regarded as a white matter (WM) disease, although over the last decade there has been a paradigm shift with rapidly accumulating evidence of widespread gray matter (GM) involvement. Cortical lesions (CLs) generally lack the classic pathological hallmarks that are seen in WM demyelination, showing little inflammation, virtually no gliosis and no blood-brain barrier disruption or complement activation (1) (2) (3) . CLs can be present in all MS subtypes but are most prominent in patients with progressive MS and after longer disease durations (1, (4) (5) (6) (7) (8) . Furthermore and importantly, CLs correlate more strongly with clinical and cognitive disability than WM lesions (WMLs) do (1, 4, 5, (8) (9) (10) (11) .
Remyelination is also frequently observed in MS lesions (12) (13) (14) (15) (16) (17) . Animal studies have shown that during a demyelinating event, oligodendrocyte (OGD) integrity and function are affected by glutamate excitotoxicity (18) , inflammatory cytokines (19) , extracellular ATP (20) , and reactive oxygen species-mediated damage (21, 22) ; these injuries may ultimately lead to OGD loss. For there to be successful remyelination, OGD precursor cells (OPCs) need to be recruited from the OPC pool that is distributed throughout the CNS (23) . Then, these cells must migrate and differentiate into mature myelinating OGDs (24) . Despite this complexity, evidence of remyelination is found in $40% of WMLs and it is even more abundant in CLs. In 2007, in an electron microscopy validated study, Albert et al estimated that approximately 75% of CLs show signs of remyelination based on a semiquantitative scoring that rated "no" (0% of lesion area remyelinated), "little" (up to 20% remyelinated), "substantial" (either confluent or patches of remyelination, 21%-60% of lesion area remyelinated) and "near complete" remyelination (61%-99% remyelinated) (4) . In 2012, Chang et al extended these findings by showing a great extent of endogenous cortical remyelination and also an abundance of OPCs in nonremyelinated CLs, suggesting a potential therapeutic target for cortical demyelination (25) .
The aim of the present study was first to confirm these findings in a large, high-quality postmortem MS sample and to score remyelination in CLs in a different large postmortem sample of MS cases using the aforementioned semiquantitative scoring method (4). Secondly, we explored possible clinical associations of the degree of cortical remyelination. Lastly, we investigated whether differences in numbers of OPCs and mature OGDs in multiple areas in GM and WM might account for the differences between GM and WM remyelination. We used immunohistochemical staining for the OPC and OGD markers Olig-2, Nogo-A and platelet-derived growth factor-a (PDGFR-a) (13, 17, (26) (27) (28) (29) (30) (31) . Specifically, our hypothesis was that lower degrees of remyelination could be explained by a smaller pool of available OPCs or OGDs in WMLs compared to CLs.
MATERIALS AND METHODS

Human Postmortem Brain Material
Postmortem brain material was obtained from the Netherlands Brain Bank (Amsterdam, The Netherlands). For assessment of the presence of WMLs and CLs, a total of 124 paraffin-embedded tissue blocks from 21 MS cases were included (13 males and 8 females). The average age of MS cases at time of death ranged from 40 to 81 years (mean 57 years 6 SD 13 years); mean postmortem delay was 8 hours (6SD, 2 hours). Clinical courses were determined by retrospective chart review blinded to pathology. Detailed patient demographics are provided in Table 1 . The study was approved by the institutional ethics review board, and all donors or their next of kin provided written informed consent for brain autopsy and use of material and clinical information for research purposes.
Immunohistochemical and Immunofluorescence Staining Protocols
Sections of all available tissue blocks were immunostained for myelin proteolipid protein (PLP), HLA-DR, Olig-2, Nogo-A, and PDGFR-a using immunohistochemical and immunofluorescence techniques (Fig. 1) . Five micrometers thick paraffin sections were collected on Superfrost Plus glass slides (VWR International, Leuven, Belgium), and dried overnight at 37 C. Sections were deparaffinized in a series of xylene (3 Â5 minutes), 100% ethanol, 96% ethanol, 70% ethanol, and water. Endogenous peroxidase activity was blocked by incubating the sections in methanol with 0.3% hydrogen peroxide.
For immunostaining for PLP, the sections were rinsed for 3 Â10 minutes with 0.01 mol/L phosphate buffered saline ([PBS], pH 7.4) followed by incubation with an anti-PLP monoclonal antibody (Clone: Plpc1; mouse IgG2a; 1:3000; Serotec, Oxford, United Kingdom), diluted in PBS containing 1% bovine serum albumin (BSA) (Roche Diagnostics, Mannheim, Germany) for 1 hour. Sections immunostained for the transcription factor Olig-2 were pretreated with Tris-EDTA buffer (pH 9.0) and microwave antigen retrieval (10 minutes at 900 W and 10 minutes at 360 W). The sections were then cooled to room temperature and rinsed 3 Â10 minutes with PBS. Subsequently, sections were incubated with primary Olig-2 antibodies (rabbit polyclonal 1:750; Millipore, Billerica, MA) diluted in PBS containing 1% BSA, at room temperature for 1 hour. Sections stained for Nogo-A with a monoclonal antibody (mouse IgG1, Clone 11C7, kindly provided by Prof. Dr M.E. Schwab University of Zurich, Switzerland) were pretreated with Tris-EDTA buffer (pH 9.0) and microwave antigen retrieval (3 minutes at 900 W and 10 minutes at 180 W). After pretreatment, sections were cooled to room temperature and rinsed in tap water. They were then incubated with 3% BSA and 1% Triton X-100 in PBS for 1 hour. After this, sections were rinsed again 3 Â10 minutes with PBS. Subsequently, sections were incubated with anti-Nogo-A diluted in antibody diluent (1:50 000) at room temperature for 1 hour.
Sections stained for anti-HLA-DR were pretreated with microwave antigen retrieval in citrate buffer (pH 6.0) (3 minutes at 900 W and 30 minutes at 180 W). After pretreatment, sections were cooled, rinsed with PBS (3Â10 minutes), and incubated with anti-HLA-DR (mouse IgG2b; 1:50, generous gift from Dr. Hilgers, VUMC, Amsterdam, The Netherlands) diluted in PBS containing 1% BSA for 1 hour.
All sections were rinsed again (3Â10 minutes) and incubated with EnVision horseradish peroxidase (HRP) complex (DAKO, Glostrup, Denmark) and finally with 3,3 0 diaminobenzidine-tetrahydrochloride dihydrate ([DAB], DAKO) as a chromogen. After a short rinse in tap water, sections were counterstained with hematoxylin for 1 minute and intensely washed with tap water for 5 minutes.
Double Staining
To verify that Olig2-weak staining serves as a sensitive and specific marker for OGDs, we performed immunohistochemical double staining for Nogo-A and Olig2. For this, sections were also pretreated with Tris-EDTA buffer (pH 9.0), microwave antigen retrieval (3 minutes at 900W and 30 minutes at 180W), cooled to room temperature and rinsed in tap water. After cooling, sections were incubated with 3% BSA and 1% Triton X-100 in PBS for 1 hour and subsequently rinsed in PBS. Then, the rinsed sections were incubated with anti-Nogo-A diluted in antibody diluent (1:100 000) and antiOlig2 (1:250) for 1 hour. The sections were then rinsed again (3Â10 minutes) and incubated with Swine-anti-Rabbit-Bio (1:300) diluted in EnVision mouse HRP (DAKO), for 30 minutes. After rinsing, sections were incubated for 1 hour with streptavidin-AF (1:100, diluted in PBS þ 1% BSA), rinsed and incubated EnVision DAB (DAKO) for 10 minutes. Finally, Olig2 was stained with liquid permanent red, shortly rinsed in tap water and finally sections were counterstained with hematoxylin.
To verify Olig2-strong staining as a marker for OPCs, fluorescence double staining was done for Olig2 and PDGFRa (goat polyclonal IgG, 1:200; R&D Systems, Minneapolis, MN). Sections were pretreated with Tris-EDTA buffer (pH 9.0) and microwave antigen retrieval (3 minutes at 900 W and 30 minutes at 180 W). After pretreatment, sections were cooled to room temperature and rinsed in water. After cooling, sections were incubated with 3% BSA and 1% Triton X-100 in Tris-buffered saline (TBS) for 1 hour and then incubated with anti-Olig2 (1:750, diluted in TBS þ 1% BSA þ Triton X-100 0.1%) and anti-PDGFR-a (1:200, diluted in TBS þ 1% BSA þ Triton X-100 0.1%) antibodies for 1 hour at room temperature. After rinsing, goat-anti-rabbit-Alexa594 (1:400; Invitrogen, Carlsbad, CA) and rabbit-anti-goat-bio (1:300) was applied for 1 hour. Again sections were rinsed and finally incubated with Avidine-Alexa488 (1:400; Invitrogen) for 1 hour.
Classification and Quantification of Demyelination
For all available tissue blocks, the presence and extent of normal-appearing WM (NAWM), normal-appearing GM Total and/or mean (SD)
57 (13) 8 (2) 35 (7) 23 (13) (NAGM), WMLs, CLs, and remyelination were scored on anti-PLP immunostained sections (Fig. 2 ). For GM, the total length (in cm) of cortex present in a tissue block was measured on the GM/WM-border. Lesions were classified as follows: Type I lesions extended across both WM and GM (leucocortical lesions); type II lesions were within the cerebral cortex and did not extend to the surface of the brain or to the subcortical WM; type III lesions consisted of all cortical lesions with extension to the brain surface but without extension to the subcortical WM; and type IV lesions extended throughout the full width of the cerebral cortex, without reaching into the subcortical WM (1). CLs were measured in a similar fashion as total GM length: By measuring the length (in cm) of the widest point of the CL projecting vertically on the GM/WM border ( Fig. 2 ). WMLs were classified according to Bö et al (32) and Trapp et al (33) . To compare GM and WM demyelination, the extent of WM demyelination was determined by measuring the length of the WML (in cm) of the WML border instead of the lesion area in cm 2 .
Classification and Quantification of Remyelination
Lesion areas were scored as remyelination when thin, irregularly formed myelin sheaths were observed. For both WMLs and CLs, remyelination was scored based on a semiquantitative score published previously by Albert et al (4) as follows: 0, no remyelination (0% of lesion area remyelinated); 1, subtle remyelination restricted to the lesion border (up to 20% of lesion are remyelinated) and 2, substantial remyelination, either confluent or patches of remyelination (21%-60% of lesion area remyelinated). A score of 3 (61%-99% of lesion area remyelinated) proved too difficult to distinguish complete remyelination from NAGM and was not used. The lengths of CLs showing remyelination were measured identically to the measurements of demyelination, i.e. on the GM/WM border. Semiquantitative scoring was performed in consensus (E.M.S. and E.J.K.). All measurements on the digital images were morphometrically measured using ImageJ software (freely downloadable from US National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/ index.html) (Fig. 3) .
Quantification of OPCs and Mature OGDs
Quantification of OPCs and OGDs was performed in the centers of lesions, remyelinated areas and normal-appearing tissue. For this, sections immunohistochemically stained for Nogo-A and Olig2 were used, as published previously (34) . Numbers of Nogo-A and Olig2-weak positive (OGDs) and Olig2-strong (OPCs)/mm 2 were determined using an ocular morphometric grid. Cell counts were performed blinded to tissue, lesion and remyelination classification and were performed 2-fold and in consensus by 2 independent raters (E.S. and E.J.K., intra-class correlation coefficient 0.92). First, a tissue area (either lesion or normal-appearing tissue in WM or GM) was chosen and cell counts were subsequently performed in a blinded manner in the corresponding area of sections stained for Nogo-A and Olig2. Because anti-Nogo-A also stains subsets of neurons, special care was taken to distinguish neurons from OGDs based on their morphology (Fig. 4) .
Statistical Analyses
Data were analyzed using SPSS software (SPSS Inc., Chicago, IL). In the case of normal distribution of data, analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons was used to compare differences among groups. When normality was not found, the nonparametric Mann-Whitney U test was used. Possible correlations were investigated with the nonparametric Spearman's rank correlation (when data were not normally distributed) or Pearson's correlation test (when data were normally distributed). To overcome bias by including multiple tissue blocks from one donor, we calculated the mean NAWM, NAGM, WMLs, CLs, and remyelination-scores for each donor for correlations among clinical characteristics. Results were considered significant when p < 0.05. 
Cortical GM and WM Descriptives and Remyelination
A mean of 6 (SD, 2) tissue blocks were analyzed for each patient. In the total 124 tissue blocks of all cases there were 248 CLs in 432 cm of inspected cortex. The mean length of cortex available for each case was 20.6 cm (range: 4.7-39.1 cm, SD 9.7 cm) ( Table 1) . Eighteen of 21 patients harbored CLs with on average 36.6% (minimum 0%, maximum 99%, SD 35.7%) of total cortex length demyelinated. In the CLs in these cases, on average 75.3% (minimum 0%, maximum 100%, SD 30.1%) of the total length of CLs showed subtle or substantial evidence of remyelination (remyelination scores 1 and 2 combined; Table 2 ). Seventy-seven WMLs were present in the available tissue (in 20/21 cases) with a mean circumference of 4.5 cm (SD 5.2 cm) and a total length of the lesion circumferences of 93.4 cm. In WMLs, remyelination was significantly less pronounced compared with CLs with a mean of 54.4% of the lesion border length showing signs of remyelination (Z ¼ À2.033, p ¼ 0.042).
Remyelination and Gender, Disease Types and Disease Duration
There was a trend toward a higher percentage of areas with any evidence of GM remyelination (ie remyelination scores 1 and 2) in the PPMS cases (mean 93.5%, SD 6.1) compared to relapsing onset (RRMS and SPMS MS cases) ( (Fig. 5) . The sample size was too small to calculate individual correlations for the different remyelination scores and disease type. There was no correlation between the extent of remyelination and age at death for the complete cohort or for the different subtypes (complete: Spearman's q ¼ 0.21; p ¼ 0.35, PPMS: Spearman's q ¼ 0.12; p ¼ 0.77, RRMS/ SPMS: Spearman's q ¼ 0.21; p ¼ 0.48). Also, no correlations were found between the extent of demyelination and disease duration and/or age at death for the complete cohort or for the different subtypes. There was also no correlation between sex and the percentage of remyelination in GM or WM for the complete cohort and different subtypes; nor was there any significant correlation between the extent of remyelination and different cortical lesion types.
Mature OGDs and OPCs: Remyelination vs Nonremyelinated Lesions vs Normal-Appearing Tissue
Nogo-A and Olig2-weak positive cell counts correlated strongly with each other when cell counts in both GM and WM were analyzed (Spearman's q ¼ 0.89; p < 0.0001). Furthermore, the co-occurrence of Olig2-strong and PDGFR-a immunostaining, and Olig2-weak and Nogo-A staining indicate that Olig2-strong cell counts do represent the number of OPCs and Olig2-weak the number of OGDs (Fig. 1 (Table 3) .
DISCUSSION
In this large, representative and well-documented series of MS autopsy cases, we showed that remyelination is more extensive in GM than in WM (75% vs 50% of total lesion lengths), with a trend toward a higher percentage of remyelination in PPMS cases. Furthermore, we show that more mature OGDs and OPCs are present in NAWM than in NAGM, and that the opposite is observed in lesions in which OPCs and mature OGDs are more frequent in CLs than in WMLs. Lastly, higher numbers of OPCs and OGDs are present in remyelinated areas within CLs compared with nonremyelinated areas within CLs, which contrasts with WMLs, where no difference was found between remyelinated and nonremyelinated areas.
In line with previous literature, we assessed remyelination based on the morphological patterns of myelin in PLP immunostainings. This morphometric scoring is based on WM remyelination where thin, irregularly formed myelin sheaths are present preferably in the presence of myelin-positive OGDs. Previous work showed that in these remyelinated WM areas electron microscopy demonstrated smaller g-ratios, indicating a thinner myelin sheath (4). Cortical remyelination is even more difficult to score than WM remyelination. To quantify the extent of GM remyelination, we applied the previously used semiquantitative scoring described by Albert et al and made a few modifications. First, we excluded their category of 3, which scores 61%-99% remyelination because normal myelination is less dense in cortical tissue compared to WM remyelination. We therefore found near-total remyelination, and scoring of the border between remyelination and normalappearing cortex was too difficult to distinguish in our sample. Because remyelination is not necessarily homogeneous within lesions, we then measured the total cortex length (cm) and Measurements of total gray matter (GM), normal-appearing gray matter (NAGM), cortical lesions and white matter (WM) lesion (WML) lengths for all included remyelination scores are shown. % total GM/WM remyelination shows the percentage of GM lesion length or WML length that show either signs of remyelination at the border (remyelination score 1) or patchy remyelination (remyelination score 2). lesion length (in cm) and scored the percentage of length of cortical lesions that showed signs of remyelination (or absence of remyelination). For consistency in data analysis and to provide an opportunity for white and GM comparison, we also expressed the total WM demyelination as length (in cm). This is in contrast to similar studies that included area (in cm 2 ). Even though the estimated extent of remyelination might as such be influenced (ie either under-or overestimated), our results still show a distribution of scores similar to the study by Albert et al. For similar reasons, cell counts were performed in lesion centers and the center of remyelinated areas instead of in the borders of each of these areas. Remyelination, especially under pathological conditions, is a complex process that is not fully understood and the 2 . N, number; NAWM, normal-appearing white matter; NAGM, normal-appearing gray matter; IQR, interquartile range. *Indicates significant differences between cell counts in corresponding areas and either NAWM or NAGM; p 0.0001. Indicates a significant difference between Nogo-A cell counts in CLs with signs of remyelination and Nogo-A cell counts in CLs without signs of remyelination; p < 0.001. mechanisms by which OGDs proliferate and mature under normal conditions are only partially known. Previous studies have shown that the maturation of OPCs into OGDs is a dynamic process in which different transcription factors are expressed during different maturation phases. In this study we used a combination of markers that have been previously used in studies addressing remyelination patterns and the identification of OPCs and OGDs in MS, i.e. PDGFR-a, olig-2 and Nogo-A. PDGFR-a is currently considered to be the most reliable marker for OPCs (35) . Nogo-A is strongly expressed in myelinating OGDs and only weakly present in neurons (27) . On the contrary, Olig-2 immunohistochemistry is more difficult because it is not a stoichiometric marker; it is expressed in OPCs (strongly) as well as in OGDs, but with a weaker intensity. In our experience, however, it is the most reliable marker for OPC and OGD staining. Previous studies have shown that Olig2-weakly positive cells are also Nogo-A-positive, and, therefore, can be identified as mature OGDs (34) . Third, the morphology of the OPCs changes during maturation. Taken together, the combination of the intensity of immunolabeling and cell morphology is reliable in identifying OGDs and OPCs in cerebral tissue. For extra certainty we performed our cell scores blinded and 2-fold by 2 independent raters, with a high interrater correlation coefficient (Spearman's q ¼0.91).
The clinical relevance and therapeutic potential of remyelination is widely acknowledged but there is no general consensus on what may drive this reparative process. Remyelination was shown to be heterogeneous and more extensive in subsets of patients (13, 36, 37) . Furthermore, remyelination is clinically associated with higher age at death and longer disease duration (38) . Yet, remyelination is not always successful and the question of why remyelination sometimes fails is highly important. However, the different mechanisms that explain failure of remyelination in MS are largely unknown (39) . Possible mechanisms include functional deficits such as exhaustion of the OPC pool or glial scar formation in lesions, which might prevent the successful recruitment of OPCs (34, 40) . Furthermore, environmental factors such as glutamate excitotoxicity or immune-mediated injury to OPCs, OGDs or the newly formed myelin sheath might be detrimental to the integrity of myelinating cells (16, 41) . Lastly, altered expression of intrinsic cellular factors such as myelination-regulating factors (e.g. LINGO-1 and PSA-NCAM [42] ), altered expression of extra-cellular factors during inflammation (e.g. semaphorins [43] ), or aging-related epigenetic alterations in OPC differentiation (44) might prevent successful maturation of OPCs into myelinating OGDs (45, 46) . None of these mechanisms has so far been conclusively proven to play a role in MS, however.
In the complex spectrum of mechanisms that influence the process of remyelination, an important observation is that there is a difference between the extent of remyelination in GM and WM. This might be explained by differences in cellular processes of remyelination in GM and WM for which we found 3 indications: 1) significantly lower numbers of OPCs and OGDs in WMLs compared with NAWM; 2) higher numbers of OPCs and OGDs in CLs compared with WMLs and 3) higher numbers of OGDs in remyelinated CLs compared with CLs without signs of remyelination. Taken together, the low numbers of premyelinating and mature myelinating cells in WMLs compared with NAWM and CLs are more indicative of profound recruitment failure, possibly caused by the presence of gliotic tissue, rather than representing a differentiation block of OPCs in the WM (34) . In addition, immune-related factors or other toxic substances in lesion areas in WM (e.g. excessive glutamate) might be lethal to recently recruited OPCs with a subsequent and ongoing relative lack of OPCs and OGDs. This might explain the somewhat surprising absence of Nogo-A-expressing mature OGDs in remyelinated WML areas (18) . The higher numbers of OPCs and OGDs in CLs and especially the significantly higher number of OGDs in remyelinated CLs might also reflect a more protective environment for myelinating cells in the human cortex, a finding that is in line with animal models showing the capacity of the cortex to repopulate with OGDs after multiple demyelinating events (47) . It could be speculated that this points toward a more effective recruitment of OPCs and differentiation process of OPCs into OGDs with ultimately more effective and widespread remyelination in GM areas.
To expand upon the clinical importance of these pathological findings, we also assessed the relationship between the extent of remyelination and clinical parameters in our sample. The main result was a trend toward a higher percentage of remyelination in PPMS, a finding that is in line with previous reports (48) . However, there were no associations with either age at death, gender, or disease duration. Although fundamentally different disease mechanisms in MS subtypes have not been reported by studies of histopathology, there are subtle differences in certain aspects of pathology among MS subtypes. In PPMS, the total WM lesion burden has reported to be less than that in relapsing-onset MS with less evidence of inflammation (49) . There is also more severe spinal cord involvement in PPMS (48, 50, 51) . Alternatively, benign MS is known for the presence of fewer CLs and fewer infratentorial lesions, while the total WM lesion load does not differ from that of RRMS patients (52) . The question to which extent remyelination contributes to a more favourable disease course remains to be answered. Of importance in this matter is that the elusiveness of this answer (in our study but also in general) is rooted in issues that are not easily overcome. Although we included a relatively large sample of tissue, the number of cases might still have been too small to generate sufficient statistical power to detect significant effects. In line with this, the heterogeneity that is present in a disease such as MS might cause small effects that are a priori difficult to be detected.
In summary, and despite some limitations, we have confirmed the previous work by Albert et al in a large and welldocumented autopsy sample and showed that GM remyelination is extensive in MS. We extended this finding by the observations that there is more remyelination in the GM than in the WM in the brains of patients with MS and a trend toward more remyelination in PPMS cases. Importantly, our results also confirm the work by Chang et al by showing that there is no substantial failure of OPC recruitment in the GM and the failure to remyelinate might better be explained by a disruption in OGD maturation. It also underscores the importance of the question as to the extent different biological mechanisms drive this variation in the expression of different phenotypes such as cortical demyelination and remyelination. It is now important for future studies to focus on a number of issues, for example, if there is spatial heterogeneity within the brain or different cortical layers regarding lesions characteristics and remyelination and whether this could explain the variation in GM remyelination as seen in this study. Since such quantification has not been performed in this study and WM and cortical areas were not derived from adjacent areas, theoretically this might account for some difference between WM and cortical lesion remyelination scores. Also, and more importantly, given that WM is significantly more inflammatory than cortical GM and given that the role of inflammation in remyelination is complex, it would be of interest to expand this study to explore the influence of local microglial inflammation on OPCs and OGDs (53) . Perhaps this might also explain in part the differences between white and GM. Furthermore, such studies should be performed including cerebral tissue from healthy controls to study the variability of "normal" myelination patterns and distribution and extent of OPCs and mature OGDs.
